

# Increasing uptake of HIV testing in the Caribbean


**Carlota Baptista da Silva**

**Global HIV, Hepatitis and STIs Programmes  
World Health Organization**

**Presenting on behalf of the WHO HHS HTS team:**

Cheryl Johnson, Alaleh Abadpour, Busisiwe Msimanga, Maggie Barr-Dichiara, Anne Bekelynck, Céline Lastrucci


# Progress toward global HIV testing targets






# HTS needs to be prioritised to achieve 95-95-95 and HIV prevention goals

Globally: 14% of all PLHIV undiagnosed




Caribbean: 15% of all PLHIV undiagnosed



Who are HTS programmes missing?

FIGURE 10.2 Distribution of acquisition of new HIV infections by population and sex (aged 15–49 years), Caribbean, 2021




Key populations (KP) and their partners/contacts  
Partners of PLHIV / STI patients  
LTFU clients needing re-engagement

High barrier service delivery models for KP, Adolescents & PLHIV

Globally – trend of new infections

Trend of new HIV infections




Change in new HIV infections since 2010

-39 %

Caribbean – trend of new infection


Trend of new HIV infections



Change in new HIV infections since 2010

-22 %

# WHO recommends HIV testing as a gateway for prevention and treatment



# WHO recommends differentiated HIV testing services


HTS approaches need to consider three dimensions for implementation:

1. **Mobilizing** and creating demand for testing
2. Testing **service delivery**
3. **Linkage** to post-test services



	Mobilizing and creating demand	HTS implementation	Linkage to care
When	Continuous, intermittent or focused	Time of day and frequency	Time period for linking and frequency of monitoring
Where	Location of mobilization activities	Health facility, other facility, community	Location of linkage activities
Who	Who does the mobilizing? Who is the focus for messages and mobilization?	Who does the HIV testing? Who is the focus for testing?	Who supports linkage to prevention or ART initiation?
What	What package of services and demand creation interventions?	What HTS approach?	What linkage intervention?

Approaches are then adapted based on the context, population and epidemic





# Priority HTS guidance for the Caribbean

## Recommendations for success - creating the right HTS environment



### Critical HTS enabler recommendations:


- All HTS following 5Cs:
  - Consent
  - Confidentiality
  - Counselling (pre-test information and post-test messages)
    - **U=U needs to be included along w/ latest information**
  - Correct results
  - Connection (linkage)
- Protect and enforce privacy
- Prevent discrimination
- Promote tolerance
- **Quality rapid HIV testing prioritization (same day results & linkage)**
- **Lay provider testing & task sharing**





# Quality of testing and prevention of misdiagnosis


1. Priority to transition to 3-test strategy
  - WHO recommends **that an HIV-positive diagnosis be made based on three consecutive HIV-reactive results**. This is increasingly important as treatment-adjusted HIV prevalence and national HTS positivity continue to decline over time. The use of 3 tests, in the right order, can increase the PPV.
  - **Testing quality is critical: Avoid misdiagnoses**
    - Using the **serial 3 test strategy in all epidemic settings**
    - Re-testing before ART initiation
    - Instituting strong quality management systems
2. **Retesting is recommended for the following people**
  - With HIV-inconclusive status, after 14 days
  - Prior to ART initiation
  - For monitoring in HIV prevention programmes – PrEP, PEP, ANC, VMMC,





# Priority HTS guidance for the Caribbean

## Recommendations for reaching priority populations with limited resources



UNAIDS/WHO  
2022

### How to deliver

#### Virtual interventions & peers

- Critical way to deliver demand creation, HIV testing services, post-test counselling and linkage support (e.g. videos, websites, social media)
- Expands reach, including to those missed by existing services (especially those not engaged in health system)
- Can be cost-efficient

### What to deliver

#### Strategic mix of HTS approaches

- Facility-based (e.g. ANC, TB, STI clinics, indicator conditions)
- Community-based (e.g. KP outreach)
- **Partner services** (i.e. provider-assisted referral & social network approaches)
- **HIV self-testing** (e.g. across facilities, communities, online, private sector)



# Network-based testing services



## WHO recommends network-based testing (NBT) services

- NBT includes partner services, family/household testing services and social network testing services.
- Partners services extended to STIs and Hep-C

## Social network testing is recommended for ALL PEOPLE with risks

- Offering HIVST within SNT may increase acceptability, feasibility, and uptake.

## Always offer provider-assisted partner services for PLHIV

Continues to be the most effective strategy

**WHO tool kit in development and release Q1 2025**

<b>Interactive decision / algorithm support:</b> Gender, age, population algorithm	<b>Clinical tools library:</b> Guides, scripts, resources for HCWs	<b>M&amp;E tools library:</b> Ethical data collection, registries, analysis and reporting	<b>Training modules:</b> How to illicit partner information, find partners, testing, IPV screening	<b>Evidence synopsis:</b> What the research shows about what works and what doesn't work for NBT


Source: Choong 2023, WHO 2024

	What can optimize SN testing approaches?
Self-tests	Can increase uptake and linkage, but can be costly. Consider resources & integration opportunities
Type of testing promoters	Important to engage community in selection appropriate for each setting
Rounds of recruitment	If resources available multiple rounds can be effective. Fewer rounds are less costly overall, but more waves important to lower cost per diagnosis if well-targeted.
Incentives	Without incentives, uptake, positivity and 1 <sup>st</sup> time tester are still high. No need for incentives
Training	Prioritize simple one-time training, as is just as effective and more practical.
Integration	Important to provide as part of a larger package of voluntary partner services / index testing

# SELF-TESTING




- **Self-testing recommended across conditions and diseases**
- **No difference in blood vs oral self-tests**
  - Both accurate and acceptable - no difference in uptake
- **HIVST recommended in health facilities**
  - Complimenting existing provider-administered HIV testing
  - Replacing risk-based screening tools
- **HIVST recommended for PEP and PrEP (oral & DVR)**
  - Covers PrEP initiation, re-initiation and continuation
  - No need for further testing to confirm negative results
  - Ongoing research for long-acting injectable PrEP is needed
- **Syphilis ST, including dual HIV/syphilis ST, recommended**
  - More multiplex ST likely in the future, Critical opportunity for integration







# How we sometimes think about a person's PrEP Journey




# In reality: People's lives and PrEP journeys are more complicated



# In reality: People's lives and PrEP journeys are more complicated



## National policy on HIV self-testing and implementation status, as of July 2023





# Conclusions

- **Enabling environment for HTS is a priority**
  - Lay providers, RDTs, ST
  - Updated messages delivered
  - Critical to have quality HTS that is accessible and enables access to ART & PrEP
  - Complex HTS algorithms and strategies need to be phased out
- **Accelerate adoption of innovation strategies for HTS**
  - Caribbean is too far behind
  - HIVST & PrEP priority for scale-up
  - Virtual services opportunities
- **Many strategic HTS approaches**
  - It's not 1-size fits all but about a strategic mix of patient-centered approaches for mobilization, testing service delivery and linkage
  - KP led services & ongoing monitoring and engagement with communities is essential

# Acknowledgements

Cheryl Johnson, Busi M, Maggie Barr-DiChiara, Céline Lastrucci, Anne Bekelynck, Aliza Monroe, Purvi Shah, Belen Dinku, Alaleh Abadpour  
All other partners for permission to use slides

For more information on HIV testing services

WHO HIV Testing Services  
Dashboard

WHO HIV Testing Services  
Info App

WHO HTS GL

Questions?

Carlota Silva [baptistic@who.int](mailto:baptistic@who.int)

# HIV testing algorithm verification toolkit




<https://www.who.int/tools/optimizing-hiv-testing-algorithms-toolkit>

- **Generic study protocol:** to assist developing local protocol to seek ethics approval
- **Test selection tool:** to assist with the selection of WHO prequalified HIV products
- **Checklist of lab consumables and reagents:** of tests and consumables to be purchased
- **Study database:** to support data analysis
- **Budget template:** to assist developing a budget of core activities
- **Gantt chart:** to assist with the planning of the verification study with timelines

# IAS Does HIVST for PrEP have negative outcomes?


*Mathematical modelling results looking at HIVST supported PrEP scale-up in 1 country*

## 1 Persons with HIV inappropriately initiated on PrEP by scenario



**HIVST does not significantly increase number of people inappropriately initiated on PrEP**


## 2 Number of individuals with NRTI Resistance over 20 years by scenario



**HIVST does not lead to significant increase in NRTI resistance**

PrEP initiations (millions)	Break-through infections (1,000s)	Acute initiated on PrEP (1,000s)	Chronic initiated on PrEP (1,000s)
<b>Nucleic acid tests (NAT)</b>			
45.55 (42.97 - 47.97)	16.50 (9.12 - 23.60)	0.09 (0 - 0.39)	0.14 (0 - 0.47)
<b>Ab RDT</b>			
45.52 (42.99 - 48.03)	16.57 (10.04 - 23.53)	0.99 (0 - 3.33)	1.91 (0.77 - 3.94)
<b>Blood HIVST</b>			
45.54 (42.99 - 48.09)	16.71 (10.12 - 23.69)	4.03 (0 - 13.54)	7.65 (0.82 - 16.54)
<b>Oral HIVST</b>			
45.53 (43.08 - 48.08)	16.65 (9.15 - 23.85)	4.49 (0 - 13.98)	13.65 (3.91 - 23.71)


**Does not significantly increase number of PLHIV missed**




**While PrEP costs increase due to more people taking and staying on PrEP, HIVST does not significantly increase costs**

# WHO recommended HIV testing strategy

## All other populations: all HIV assays



## ANC/KP settings: dual HIV-Syphilis rapid test



A1: Assay 1, A2: Assay 2, A3: Assay 3, TP: *Treponema pallidum* (syphilis).  
 A1 (Assay 1) is a dual HIV/syphilis rapid diagnostic test (RDT).  
 A2 and A3 (Assay 2 and Assay 3) are HIV RDTs or enzyme immunoassays (EIAs).  
 When resolving discrepant results, all reactive TP (syphilis) results, including A1:TP+ or Repeat A1: TP+, should be referred for treatment and further testing according to national guidelines.  
 When resolving discrepant results, if A1 and Repeat A1 are both TP (syphilis) nonreactive results, report syphilis-negative.

A1: Assay 1 (first test); A2: Assay 2 (second test); A3: Assay 3 (third test).

**Switching to ST & RDT-based strategies brings new opportunities – including integration with dual HIV/syphilis testing which is also critical for Caribbean**

## Summary of new and updated recommendations

### Self-testing

**NEW:** HIV self-testing may be offered as an additional option for testing at facilities (*conditional recommendation, low-certainty evidence*).

**NEW:** HIV self-testing may be used to deliver pre-exposure prophylaxis, including for initiation, re-initiation and continuation (*conditional recommendation, low-certainty evidence*).

**NEW:** Syphilis self-testing is suggested as an additional approach to syphilis testing services (*conditional recommendation, low-certainty evidence*).

### Network-based testing services

**NEW:** STI partner services should be offered to people with STIs as part of a range of options based on their needs and preferences and within a comprehensive package of voluntary STI testing, care and prevention (*strong recommendation, low-certainty evidence*).

**UPDATED:** Social network testing services may be offered as an additional HIV testing approach as part of a comprehensive package of care and prevention (*conditional recommendation, low-certainty evidence*).

### HIV testing strategies



**NEW:** HIV recency testing is not recommended as part of routine HIV testing services (*conditional recommendation, low-certainty evidence*).

# HIV self-testing for PrEP and PEP

## HIV self-testing may be used to deliver pre-exposure prophylaxis, including for initiation, re-initiation and continuation (conditional)

- HIVST can be used for initiation, continuation and re-initiation of PrEP
- Could simplify PrEP delivery by reducing the need for frequent clinic visits
- Should be driven by client needs and preferences
- HIVST in PrEP helps streamline HTS requirements for oral PrEP (daily and on-demand) and the dapivirine ring (DVR)
- No need for further testing to confirm negative results
- HIVST to be considered for post-exposure prophylaxis (PEP)
- Ongoing research on the role of HIVST in the use of long-acting injectable PrEP (CAB-LA)

## HIV self-testing for PrEP




# WHO recommendation on HCV self-testing

**Hepatitis C virus (HCV) self-testing should be offered as an additional approach to HCV testing services**

*(strong recommendation, moderate-certainty evidence)*

## Remarks

- HCV self-testing needs to be followed by **linkage to appropriate post-test services**, including confirmation of viraemic infection, treatment, care and referral services, according to national standards.
- It is desirable to **adapt HCV self-testing service delivery and support options** to the national and local context, which includes community preferences.
- **Communities, including networks of key and vulnerable populations and peer-led organizations, need to be meaningfully and effectively engaged** in developing, adapting, implementing, and monitoring HCV self-testing programmes.



# Syphilis Self-testing



**WHO suggests offering syphilis self-testing as an additional syphilis testing approach** (*conditional recommendation, low certainty in evidence of effects*)

- Offer within broader programme and package of services - access and linkage to confirmatory testing (where available) and immediate treatment initiation
- **Quality-assured products**
- **Epidemiology and context:** where to deliver self-testing to specific populations and in certain geographies.
- **Clear messages : confirmatory testing and treatment**

- 5 studies reported on dual HIV/syphilis self-tests
- 2 reported on single syphilis self-tests
- None on T/NT RDT
- **Greater testing uptake (p=0.03)**
- **No significant difference in test reactivity**
- **No significant difference in linkage to confirmatory testing**
- **No evidence of increased social harm or adverse event.**
- **High acceptability among MSM, TGW and FSW & providers in China, Zimbabwe and the US**
- **Lower cost per person tested than existing facility-based testing (China and Zimbabwe)**